Local chemotherapy has a stronger effect on reducing tumor growth

March 14, 2013
Local chemotherapy has a stronger effect on reducing tumor growth
Mariska de Smet (left) prepares the temperature-sensitive liposomes. Credit: TU Eindhoven/Philips Research

Reducing the growth of a tumor by localized delivery of cancer medication can be achieved by using a combination of ultrasound, temperature-sensitive nanoparticles and MRI. This is shown by Mariska de Smet in her PhD research at Eindhoven University of Technology (TU/e) and Philips Research. Her preclinical studies show that this local chemotherapy is more effective in reducing tumor growth than regular chemotherapy. In addition, the amount of medication reaching the tumor can be measured by adding an imaging marker to the chemo. De Smet defends her thesis on Thursday March 14th.

Using chemotherapy to treat cancer always has unpleasant side effects. The of the medication also affect healthy cells, as well as those of the tumor itself. This leads to symptoms like nausea, hair loss or reduced effectiveness of the immune system. Scientists have been working for many years on image-guided administration of medication using 'delivery vehicles': particles that transport the medication through the body to the tumor, which can be imaged after drug release. This allows higher doses of medication to be used, while the rest of the patient's body remains unaffected.

Temperature-sensitive

TU/e and Philips Research have been carrying out research for a number of years into methods of this kind, in which temperature-sensitive liposomes (tiny fat-based spheres) act as for the medication. The liposomes contain the medication and a that is visible in an . After injection into the blood, the liposomes transport the medication through the body. The location of the tumor is identified using MRI, after which the tumor is warmed by means of ultrasound. When the liposomes reach the tumor, the increased temperature causes them to open so that the medication and contrast medium are released.

Slowing down tumor growth

Mariska de Smet shows the effectiveness of this method in her PhD research at TU/e, in which she was supervised by prof.dr. Holger Grüll. was found to be reduced after treatment using this technique. In fact the effect was even stronger than with regular chemotherapy. De Smet also showed that the amount of contrast agent released was a good indicator of the extent to which tumor growth was slowed down; the more contrast medium visible, the greater the effect of the chemotherapy. Because the amount of medicine released can immediately be measured, this could enable physicians in the future to quickly decide whether to administer additional medication or to start a different form of treatment.

Clinical development

The research carried out by De Smet was of a preclinical nature. Before the therapeutic effects of the method can be investigated on patients, a number of practical obstacles still need to be overcome. De Smet expects that it will take 10 - 15 years before the new technology is available for use on patients.

Explore further: Breast MRI helps predict chemotherapy's effectiveness

More information: Mariska de Smet will gain her PhD on the 14th March at Eindhoven University of Technology for her thesis entitled 'MR-HIFU mediated local drug delivery using temperature-sensitive liposomes'.

Related Stories

Breast MRI helps predict chemotherapy's effectiveness

May 23, 2012
Magnetic resonance imaging (MRI) provides an indication of a breast tumor's response to pre-surgical chemotherapy significantly earlier than possible through clinical examination, according to a new study published online ...

A combination of TH-302 and radiation reduced human pancreatic tumor growth in hypoxic xenografts

June 19, 2012
A combination of the prodrug TH-302 and radiation may provide an effective treatment strategy for pancreatic cancer, according to preclinical results presented at the American Association for Cancer Research's Pancreatic ...

Iron key to brain tumor drug delivery

June 2, 2011
Brain cancer therapy may be more effective if the expression of an iron-storing protein is decreased to enhance the action of therapeutic drugs on brain cancer cells, according to Penn State College of Medicine researchers.

Recommended for you

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

Novel CRISPR-Cas9 screening enables discovery of new targets to aid cancer immunotherapy

July 19, 2017
A novel screening method developed by a team at Dana-Farber/Boston Children's Cancer and Blood Disorders Center—using CRISPR-Cas9 genome editing technology to test the function of thousands of tumor genes in mice—has ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.